Subscribe To
Acceptance of polyamine inhibitor car-t combination abstract for online publication
MINNEAPOLIS, Oct. 25, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics...
October 25, 2023, 12:15 pm
Panbela announces poster presentation at the endocrine society meeting: polyamine inhibition and β-cell preservation in recent onset type 1 diabetes
MINNEAPOLIS, June 26, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disru...
June 26, 2023, 12:15 pm
Panbela announces sponsored research agreement to evaluate polyamine metabolic inhibitor therapy in combination with car-t cell therapy
MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) — Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutic...
June 13, 2023, 12:15 pm